RLMD insider trading
NasdaqCM HealthcareRELMADA THERAPEUTICS, INC.: insider trade history from SEC Form 4 filings.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Company website: www.relmada.com
RLMD insider activity at a glance
FilingIQ tracks 225 insider transactions for RLMD in filings since Dec 16, 2015. The most recent transaction is dated Sep 10, 2026.
Across the full history, 91 open-market purchases
and 86 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RLMD insider trades is 56.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RLMD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RLMD?
- FilingIQ tracks 225 Form 4 insider transactions for RLMD (RELMADA THERAPEUTICS, INC.), covering filings from Dec 16, 2015 onwards. 4 of those are dated within the last 90 days.
- Are RLMD insiders net buyers or net sellers?
- Across the full Form 4 history for RLMD, 91 transactions (40%) were open-market purchases and 86 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RLMD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RLMD in?
- RELMADA THERAPEUTICS, INC. (RLMD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $319.73M.
Methodology & sources
Every RLMD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.